BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, May 14, 2025
Breaking News: US FDA clears Abbvie’s c-Met lung cancer ADC Breaking News: 100 days of uncertaintyBreaking News: 100 days of uncertainty
Home » Topics » BioWorld

BioWorld
BioWorld RSS Feed RSS

Other news to note for Oct. 7, 2024

Oct. 7, 2024
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Relay.
Read More

In the clinic for Oct. 7, 2024

Oct. 7, 2024
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Biodexa, Relief, Ultragenyx.
Read More

Appointments and advancements for Oct. 7, 2024

Oct. 7, 2024
New hires and promotions in the biopharma industry, including: Galapagos, Inozyme, Mosaic, Myricx, Oak Hill.
Read More

Financings for Oct. 7, 2024

Oct. 7, 2024
Biopharmas raising money in public or private financings, including: Editas, Humacyte, Onconetix, Sirnaomics, Sonnet Biotherapeutics, Vertex.
Read More
Biomarkers

Nobel Prize in Physiology or Medicine for discovering microRNA

Oct. 7, 2024
By Mar de Miguel
Research into the regulation of gene expression experienced a significant breakthrough with the discovery of microRNA, small RNA molecules that do not code for proteins but control their translation. This finding has earned its authors Victor Ambros and Gary Ruvkun the 2024 Nobel Prize in Physiology or Medicine.
Read More
Illustration of Victor Ambros and Gary Ruvkun
Biomarkers

Two win Nobel for microRNA work

Oct. 7, 2024
By Mar de Miguel
Research into the regulation of gene expression experienced a significant breakthrough with the discovery of microRNA, small RNA molecules that do not code for proteins but control their translation. This finding has earned its discoverers – Victor Ambros and Gary Ruvkun – the 2024 Nobel Prize in Physiology or Medicine “for the discovery of microRNA and its role in post-transcriptional gene regulation.”
Read More

Biopharma money raised: Jan. 1-Oct. 3, 2024

Oct. 4, 2024
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More

BioWorld and Nasdaq stock indices

Oct. 4, 2024
These graphs compare the performance of the biotech stocks for all of 2024 using the BioWorld Stock Indicator and the Nasdaq Biotech Index.
Read More

Money raised by biopharma

Oct. 4, 2024
Total raised in public, private and other financings of biopharma companies, comparing 2019-2024.
Read More

Biopharma money raised by quarter in 2024 (US$M)

Oct. 4, 2024
Biopharma money raised to-date and by month in 2023, including public, private and other financings.
Read More
Previous 1 2 … 183 184 185 186 187 188 189 190 191 … 8749 8750 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 14, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 14, 2025.
  • Koreabio Humanase KOH Sungho

    FDA shift from animal testing fuels organoid, organ-on-chip demand

    BioWorld Science
    The U.S. FDA’s decision to phase out animal testing for INDs is driving a new market of alternative, nonanimal testing technologies like organoids and...
  • Pills, bottle, scale and-measuring tape

    Septerna joins a $2.2B obesity deal with Novo

    BioWorld
    In a deal that could top out at about $2.2 billion, Septerna Inc. is getting $200 million up front from Novo Nordisk A/S in a collaboration to develop oral...
  • AI generated, 3D rendering of protein degradation

    AACR 2025: Induced proximity strategy, beyond degraders

    BioWorld
    Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing